Efficacy News and Research

RSS

Vitamin D2 supplementation is promising treatment for pain, depression in type 2 diabetes

Vitamin D decreases pain in women with type 2 diabetes and depression, according to a study conducted at Loyola University Chicago. These findings were presented at an Oct. 24, 2013 research conference at Loyola's Health Sciences Campus.

2 Dec 2013

Four-drug regimen shows first-line efficacy in advanced NSCLC

A four-drug combination of cetuximab, bevacizumab, carboplatin, and paclitaxel is effective and has acceptable safety as a first-line treatment for advanced non-small-cell lung cancer, US researchers report.

2 Dec 2013

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease.

2 Dec 2013

Nanosponge vaccine blocks adverse effects of alpha-haemolysin toxin from MRSA

Nanosponges that soak up a dangerous pore-forming toxin produced by MRSA (methicillin-resistant Staphylococcus aureus) could serve as a safe and effective vaccine against this toxin. This "nanosponge vaccine" enabled the immune systems of mice to block the adverse effects of the alpha-haemolysin toxin from MRSA-both within the bloodstream and on the skin. Nanoengineers from the University of California, San Diego described the safety and efficacy of this nanosponge vaccine in the December 1 issue of Nature Nanotechnology.

2 Dec 2013

Osiris: CMS releases proposed ruling for reimbursement of skin substitutes in hospital outpatient setting

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products in orthopedics, sports medicine and wound care, announced today that, on November 27, 2013, the Centers for Medicare and Medicaid Services released their proposed ruling for the reimbursement of skin substitutes in the hospital outpatient setting. CMS decided to package the reimbursement for products used in advanced wound care with the related surgical procedure into a two-tier system.

30 Nov 2013

UC San Diego biophysicists discover how antibiotic resistance allows bacteria to multiply

Using quantitative models of bacterial growth, a team of UC San Diego biophysicists has discovered the bizarre way by which antibiotic resistance allows bacteria to multiply in the presence of antibiotics, a growing health problem in hospitals and nursing homes across the United States.

30 Nov 2013

Study reveals new mechanism that may block formation of new blood vessels and cancer growth

A study led by researchers at Boston University School of Medicine demonstrates a new mechanism involving a signaling protein and its receptor that may block the formation of new blood vessels and cancer growth. The findings are published in the December issue of Science Signaling.

29 Nov 2013

Health insurance coverage does not increase risky behavior

People with health insurance are more likely to use preventive services such as flu shots and health screenings to reduce their risk of serious illness, but they are no more likely than people without health insurance to engage in risky health behaviors such as smoking or gaining weight, researchers at UC Davis and University of Rochester have found.

27 Nov 2013

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets.

27 Nov 2013

Research: Human neural stem cells could improve blood flow in critical limb ischemia

New research has shown human neural stem cells could improve blood flow in critical limb ischemia through the growth of new vessels. Critical limb ischemia is a disease that severely obstructs arteries and reduces the blood flow to legs and feet. CLI remains an unmet clinical problem and with an ageing population and the rise in type II diabetes, the incidence of CLI is expected to increase.

27 Nov 2013

QRxPharma refiles MOXDUO New Drug Application with US FDA

QRxPharma Limited announced today that the Company resubmitted its MOXDUO New Drug Application. At a meeting in early October, the United States Food and Drug Administration provided QRxPharma with guidance on its requirements for the NDA refiling as well as data validation documentation.

26 Nov 2013

Researchers successfully target T lymphocytes which play key role in body's immune response

Researchers at the University of California, San Diego School of Medicine have successfully targeted T lymphocytes - which play a central role in the body's immune response - with another type of white blood cell engineered to synthesize and deliver bits of non-coding RNA or microRNA (miRNA).

26 Nov 2013

Icahn School of Medicine receives $2.7M to investigate narrow pathway targeted immune therapy

The National Institutes of Health has awarded a research team at the Icahn School of Medicine at Mount Sinai $2.7 million to study systemic treatments for patients with moderate to severe atopic dermatitis (AD), also known as eczema.

26 Nov 2013

EMA grants accelerated assessment to Boehringer Ingelheim's Faldaprevir compound

The application for European marketing authorisation of faldaprevir, a potent second generation oral protease inhibitor, has been fully validated and granted accelerated assessment by the European Medicines Agency (EMA).

26 Nov 2013

Sacral neuromodulation stands test of time in LUTD

Follow-up of patients at a Belgian institution reveals that sacral neuromodulation is effective for the treatment of lower urinary tract dysfunction over the long term, but often requires reintervention.

From Medtronic 25 Nov 2013

DSMB reviews safety data from Phase I/IIa clinical trial of NTCELL for Parkinson’s disease

Living Cell Technologies Limited today announced that the independent data safety monitoring board has reviewed the safety data from the initial patient in the Phase I/IIa clinical trial of NTCELL and advised that implants for the additional three patients in the trial can proceed.

25 Nov 2013

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration has approved OLYSIO (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis.

23 Nov 2013

Research paves way towards personalized chronotherapy treatments

Cancer chronotherapy consists in administering treatment at an optimal time. Because the body is governed by precise biological rhythms, the efficacy of anti-cancer drugs can be doubled and their toxicity reduced five-fold depending on the exact timing of their administration.

22 Nov 2013

MEMREHAB Trial shows significant effect for cognitive rehabilitation in MS

Kessler Foundation researchers published the results of the MEMREHAB Trial in Neurology, the medical journal of the American Academy of Neurology, providing the first Class I evidence for the efficacy of cognitive rehabilitation in multiple sclerosis. The article, Chiaravalloti N, Moore NB, Nikelshpur OM, DeLuca D: An RCT to treat learning impairment in MS. Neurology 2013(81), was released as an epub ahead of print on November 8

22 Nov 2013

Probe to measure immune function could lead to determine nanoparticle-based drugs for cancer patients

The development of a probe to measure the body's immune function could lead to more accurate, individualized doses for cancer patients prescribed nanoparticle-based drugs, according to research conducted at the University of North Carolina.

21 Nov 2013

Efficacy News and Research

Vitamin D2 supplementation is promising treatment for pain, depression in type 2 diabetes

Four-drug regimen shows first-line efficacy in advanced NSCLC

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Nanosponge vaccine blocks adverse effects of alpha-haemolysin toxin from MRSA

Osiris: CMS releases proposed ruling for reimbursement of skin substitutes in hospital outpatient setting

UC San Diego biophysicists discover how antibiotic resistance allows bacteria to multiply

Study reveals new mechanism that may block formation of new blood vessels and cancer growth

Health insurance coverage does not increase risky behavior

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Research: Human neural stem cells could improve blood flow in critical limb ischemia

QRxPharma refiles MOXDUO New Drug Application with US FDA

Researchers successfully target T lymphocytes which play key role in body's immune response

Icahn School of Medicine receives $2.7M to investigate narrow pathway targeted immune therapy

EMA grants accelerated assessment to Boehringer Ingelheim's Faldaprevir compound

Sacral neuromodulation stands test of time in LUTD

DSMB reviews safety data from Phase I/IIa clinical trial of NTCELL for Parkinson’s disease

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

Research paves way towards personalized chronotherapy treatments

MEMREHAB Trial shows significant effect for cognitive rehabilitation in MS

Probe to measure immune function could lead to determine nanoparticle-based drugs for cancer patients

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News